日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Small-molecule MMRi36 induces apoptosis in p53-mutant lymphomas by targeting MDM2/MDM4/XIAP for degradation.

小分子 MMRi36 通过靶向 MDM2/MDM4/XIAP 进行降解，诱导 p53 突变淋巴瘤细胞凋亡

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2024.1462231
Lama Rati, Wu Wenjie, Mavis Cory K, Ruiz Federico M, Querol-García Javier, Martin Diana, Chemler Sherry R, Chandra Dhyan, Goodrich David W, Hernandez-Ilizaliturri Francisco J, Muñoz Inés G, Wang Xinjiang
细胞生物学
MDM2
P53
凋亡
发表日期：2024
文献求助 收藏

Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia

靶向抑制BET的OPN-51107与维奈托克在慢性淋巴细胞白血病中具有协同作用。

期刊:Leukemia & Lymphoma
影响因子:2.2
doi:10.1080/10428194.2024.2398663
Zablonski, Kevin G; Skupa, Sydney A; Eiken, Alexandria P; Sundaram, Suchitra; Mavis, Cory; Gu, Juan Jenny; Torka, Pallawi; Ghione, Paola; El-Gamal, Dalia; Hernandez-Ilizaliturri, Francisco J
白血病
细胞生物学
发表日期：2024
文献求助 收藏

Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

卡非佐米联合利妥昔单抗、异环磷酰胺、卡铂和依托泊苷治疗复发/难治性弥漫性大B细胞淋巴瘤成人患者的群体药代动力学和药效学研究

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-023-00992-4
Lin, Lan-Hsi; Ghasemi, Mohammad; Burke, Sarah M; Mavis, Cory K; Nichols, Jenna R; Torka, Pallawi; Mager, Donald E; Hernandez-Ilizaliturri, Francisco J; Goey, Andrew K L
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2023
文献求助 收藏

Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study

奥法妥木单抗联合HyperCVAD/HD-MA诱导治疗可使新诊断的套细胞淋巴瘤患者达到较高的微小残留病灶阴性率：一项II期研究的结果

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.34106
Torka, Pallawi; Akhtar, Othman S; Reddy, Nishitha M; Baysal, Bora E; Kader, Angela; Groman, Adrienne; Nichols, Jenna; Mavis, Cory; Tario, Joseph D; Block, AnneMarie W; Sait, Sheila N J; Ghione, Paola; Sundaram, Suchitra; Przespolewski, Eugene R; Mohr, Alice; Lund, Ian; Kostrewa, Jessica; McWhite, Kenneth; DeMarco, Joseph; Johnson, Michael; Darrall, Andrea; Thomas-Talley, Rosh-Neke; Wallace, Paul K; Neppalli, Vishala; Hutson, Alan; Hernandez-Ilizaliturri, Francisco J
细胞生物学
淋巴瘤
发表日期：2022
文献求助 收藏

Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status

小分子MMRi62靶向MDM4使其降解，并诱导白血病细胞凋亡，且该作用不受p53状态的影响。

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2022.933446
Lama, Rati; Xu, Chao; Galster, Samuel L; Querol-García, Javier; Portwood, Scott; Mavis, Cory K; Ruiz, Federico M; Martin, Diana; Wu, Jin; Giorgi, Marianna C; Bargonetti, Jill; Wang, Eunice S; Hernandez-Ilizaliturri, Francisco J; Koudelka, Gerald B; Chemler, Sherry R; Muñoz, Inés G; Wang, Xinjiang
凋亡
表观遗传
多发性骨髓瘤
MDM4
白血病
细胞生物学
发表日期：2022
文献求助 收藏

Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy

接受B细胞靶向治疗的淋巴瘤患者对COVID-19疫苗反应的决定因素

期刊:
影响因子:
doi:10.1182/blood-2021-152738
Ghodse, Hamid; Goel, Shipra; Gu, Juan J; Torka, Pallawi; Mavis, Cory; Sundaram, Suchitra; Neiders, Mirdza; Suresh, Lakshmanan; Shen, Long; Ramsperger, Vince; Griffiths, Elizabeth A; Segal, Brahm; Hernandez-Ilizaliturri, Francisco J; Ghione, Paola
淋巴瘤
细胞生物学
B细胞
免疫/内分泌
发表日期：2021
文献求助 收藏

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.

利妥昔单抗治疗后弥漫性大B细胞淋巴瘤中粘附分子ICAM-1：与预后重要性和利妥昔单抗耐药性的关系

期刊:Aging-Us
影响因子:3.9
doi:10.18632/aging.202180
Liu Yizhen, Gu Juan J, Yang Ling, Tsai Ping-Chiao, Guo Ye, Xue Kai, Xia Zuguang, Liu Xiaojian, Lv Fangfang, Cao Junning, Hong Xiaonan, Mavis Cory, Hernandez-Ilizaliturri Francisco J, Zhang Qunling
细胞生物学
发表日期：2020
文献求助 收藏

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents

伏立诺他（Vorinostat）是一种组蛋白去乙酰化酶（HDAC）抑制剂，可促进细胞周期阻滞，并使对利妥昔单抗和化疗耐药的淋巴瘤细胞重新对化疗药物敏感。

期刊:Journal of Cancer Research and Clinical Oncology
影响因子:2.8
doi:10.1007/s00432-015-2026-y
Xue, Kai; Gu, Juan J; Zhang, Qunling; Mavis, Cory; Hernandez-Ilizaliturri, Francisco J; Czuczman, Myron S; Guo, Ye
细胞生物学
淋巴瘤
表观遗传
乙酰化
发表日期：2016
文献求助 收藏

The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma

新型蛋白酶体抑制剂卡非佐米可诱导细胞周期阻滞和凋亡，并增强利妥昔单抗耐药淋巴瘤的化疗抗肿瘤活性。

期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/bjh.12452
Gu, Juan J; Hernandez-Ilizaliturri, Francisco J; Kaufman, Gregory P; Czuczman, Natalie M; Mavis, Cory; Skitzki, Joseph J; Czuczman, Myron S
肿瘤
凋亡
表观遗传
肿瘤免疫
淋巴瘤
细胞生物学
发表日期：2013
文献求助 收藏

MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models

MLN2238 是一种蛋白酶体抑制剂，可诱导 caspase 依赖性细胞死亡和细胞周期阻滞，并增强利妥昔单抗化疗敏感或耐药的 B 细胞淋巴瘤临床前模型中化疗药物的细胞毒活性。

期刊:Anti-Cancer Drugs
影响因子:2.2
doi:10.1097/CAD.0000000000000008
Gu, Juan J; Hernandez-Ilizaliturri, Francisco J; Mavis, Cory; Czuczman, Natalie M; Deeb, George; Gibbs, John; Skitzki, Joseph J; Patil, Ritesh; Czuczman, Myron S
细胞生物学
淋巴瘤
T细胞
发表日期：2013
文献求助 收藏